ARS Pharmaceuticals Inc (SPRY) receives a Sector outperform rating from Scotiabank

ARS Pharmaceuticals Inc’s filing revealed that its 10% Owner Flynn James E unloaded Company’s shares for reported $13.66 million on Jun 27 ’25. In the deal valued at $18.46 per share,740,149 shares were sold. As a result of this transaction, Flynn James E now holds 4,887,254 shares worth roughly $78.64 million.

Then, ERIC KARAS bought 15,000 shares, generating $254,859 in total proceeds.

Before that, Karas Eric sold 15,000 shares. ARS Pharmaceuticals Inc shares valued at $240,000 were divested by the Chief Commercial Officer at a price of $16.00 per share. As a result of the transaction, Karas Eric now holds 7,696 shares, worth roughly $0.12 million.

Scotiabank initiated its ARS Pharmaceuticals Inc [SPRY] rating to a Sector outperform in a research note published on March 07, 2025; the price target was $30. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early February with a ‘”an Outperform”‘ rating. Cantor Fitzgerald began covering SPRY with “an Overweight” recommendation on August 20, 2024. Raymond James revised its rating on August 13, 2024. It rated SPRY as “a Strong buy” which previously was an “an Outperform”.

Price Performance Review of SPRY

On Tuesday, ARS Pharmaceuticals Inc [NASDAQ:SPRY] saw its stock fall -7.79% to $16.09. Over the last five days, the stock has lost -4.11%. ARS Pharmaceuticals Inc shares have risen nearly 99.88% since the year began. Nevertheless, the stocks have risen 52.51% over the past one year. While a 52-week high of $18.90 was reached on 06/27/25, a 52-week low of $8.35 was recorded on 03/04/25.

Levels Of Support And Resistance For SPRY Stock

The 24-hour chart illustrates a support level at 15.59, which if violated will result in even more drops to 15.09. On the upside, there is a resistance level at 17.00. A further resistance level may holdings at 17.91.

How much short interest is there in ARS Pharmaceuticals Inc?

A steep rise in short interest was recorded in ARS Pharmaceuticals Inc stocks on 2025-06-13, dropping by -1.65 million shares to a total of 16.58 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 18.23 million shares. There was a decline of -9.98%, which implies that there is a negative sentiment for the stock.

The most recent change occurred on August 12, 2024 when Leerink Partners resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $20.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.